"We are delighted to welcome Chris to our management team. He has extensive experience in corporate finance and has advised a wide variety of biopharmaceutical companies as they developed their pipelines and commercialized their products," said Julia C. Owens, Ph.D., President and Chief Executive Officer of Millendo. "His expertise will be instrumental to the development and implementation of our financial strategy as we continue to progress our product candidates in four endocrine disease areas."
Prior to joining Millendo, Mr. Seiter served as a Managing Director at Bank of America Merrill Lynch in the firm's healthcare investment banking group. In this capacity, he advised life sciences companies and facilitated transactions ranging from equity and debt financings to mergers and acquisitions. During his 17-year tenure there, Chris held various roles of increasing responsibility, including Head of Life Sciences Investment Banking. Prior to that, Mr. Seiter worked in the healthcare investment banking groups at UBS, Dillon Read and Kidder Peabody. Before his career in investment banking, Mr. Seiter served in the U.S. Navy as a nuclear submarine officer for five years. Mr. Seiter earned a B.A. in economics cum laude from the University of Rochester and completed a graduate level program in nuclear engineering at the U.S. Naval Nuclear Power School.
"I am thrilled to join Millendo at this important time in the Company's growth," commented Mr. Seiter. "This is an exciting opportunity to utilize my background in corporate finance to provide guidance and leadership as the Company advances its pipeline of novel medicines for patients with endocrine diseases that have few or no approved therapies."
About Millendo Therapeutics, Inc.
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases caused by hormone dysregulation. We are currently advancing two product candidates to treat four diseases. Based on our understanding of the novel biology underlying hormone dysregulation in endocrine diseases, we are developing our product candidates for conditions where current therapies are insufficient. Our clinical programs are designed to address:
View source version on businesswire.com: http://www.businesswire.com/news/home/20161117005619/en/
Source: Millendo Therapeutics, Inc.
To read more People News articles, click here.